Intellia's $108M IPO Leads Pair Of Biotech Floats
Intellia Therapeutics Inc., a preclinical biotech that develops gene editing therapies, priced an upsized initial public offering on Thursday, bringing in $108 million, as Spring Bank Pharmaceuticals Inc. reduced its already...To view the full article, register now.
Already a subscriber? Click here to view full article